Article

Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancer

2024-04-22

Abstract excerpt

<title>Abstract</title> <p>Though there has been substantial progress in the development of anti-HER2 therapies to treat HER2-positive metastatic breast cancer (MBC) within the past two decades, most patients still experience disease progression and cancer-related death. HER2-directed tyrosine kinase inhibitors (TKIs) can be highly effective therapies for patients with HER2-positive MBC, however, an understanding...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d3926793-aa7d-521b-babe-8570d8a2eb1d
DOI: 10.21203/rs.3.rs-4270758/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancerDOI 10.21203/rs.3.rs-4270758/v1Read

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancerSemantic proximity Read

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read

Concurrent Mutations Associated With Trastuzumab-resistance Revealed by Single Cell SequencingSemantic proximity Read

Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.Semantic proximity Read

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerSemantic proximity Read

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer.Semantic proximity Read

FGFR gene amplification and response to HER2-targeted therapy in patients with HER2-expressing metastatic breast cancerSemantic proximity Read

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity Read

Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumoursSemantic proximity Read

Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.Semantic proximity Read

Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.Semantic proximity Read

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.Semantic proximity Read